Back to top
more

Omega Therapeutics (OMGA)

(Delayed Data from NSDQ)

$2.19 USD

2.19
493,640

-0.28 (-11.34%)

Updated May 21, 2024 04:00 PM ET

After-Market: $2.17 -0.02 (-0.91%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 5.26% and 155.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?

by Zacks Equity Research

Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.

Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Omega Therapeutics (OMGA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

by Zacks Equity Research

Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.

Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Omega Therapeutics (OMGA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Omega Therapeutics (OMGA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 19.57% and 6.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Sutro Biopharma (STRO) delivered earnings and revenue surprises of 151.22% and 834.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk

by Zacks Equity Research

Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.

Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs

by Zacks Equity Research

Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.

Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -5.88% and 21.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing

by Zacks Equity Research

Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.

J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps

by Zacks Equity Research

J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.

Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal

by Zacks Equity Research

Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.

Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why

by Zacks Equity Research

Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.

Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss

by Zacks Equity Research

Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.

Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises

by Zacks Equity Research

Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.

BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study

by Zacks Equity Research

BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.

Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data

by Zacks Equity Research

Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.

Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why

by Zacks Equity Research

Apellis' (APLS) shares have rallied 62% over the past six months due to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake of its first marketed product, Empaveli, has further bolstered the stock value.

Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery

by Zacks Equity Research

Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.

Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301

by Zacks Equity Research

Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.

ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study

by Zacks Equity Research

ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.

Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study

by Zacks Equity Research

Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable or metastatic urothelial carcinoma.